STK-012 is under clinical development by Synthekine and currently in Phase I for Metastatic Melanoma. According to GlobalData, Phase I drugs for Metastatic Melanoma have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how STK-012’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
STK-012 is under development for the treatment of solid tumors including renal cell carcinoma, cervical cancer, non-small cell lung cancer, head and neck cancer squamous cell carcinoma and metastatic melanoma. It comprises of engineered Interleukin-2 (IL-2) and acts by targeting IL-2 receptors. It is administered through subcutaneous route.
It was also under development for the treatment of ovarian cancer.
Synthekine is a biotherapeutics company focused on of novel specific, selective and potent cytokine therapies for the treatment of cancer and autoimmune disorders. The company is investigating its lead programs candidate in IND-enabling development STK-012, an engineered Interleukin-2 (IL-2) partial agonist targeting cancer, STK-009 and SYNCAR-001, an orthogonal IL-2 ligand designed to selectively activate CAR-Ts and other adoptive cell therapies (ACTs) in vivo to improve efficacy CAR-Ts and other ACTs by data evaluation. Synthekine is headquartered in Menlo Park, California, the US.
For a complete picture of STK-012’s drug-specific PTSR and LoA scores, buy the report here.